These results raise the possibility that pharmacological manipulation of PKCβ may lead to loss of body fat and may suggest novel therapeutic strategies for obesity and obesity-related disorders. The gene discussed is PRKCB; the disease is obesity due to melanocortin 4 receptor deficiency.